Arbutus Biopharma

$2.68 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Arbutus Biopharma

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing cure for people with chronic hepatitis B virus (HBV) infection. Its product pipeline is focused on finding curative combination regimen for chronic HBV infection, with the objective of developing a suite of products that intervene at different points in the viral life cycle and reactivate the host immune system. It is developing a product pipeline consisting of multiple drug candidates with complementary mechanisms of action. The Company’s HBV product pipeline includes ribonucleic acid (RNA) interference (RNAi) therapeutics, oral capsid inhibitors, oral compounds that inhibit programmed death-ligand one (PDL1) and oral HBV RNA destabilizers. Its subsidiaries include Arbutus Inc and Arbutus Biopharma US Holdings, Inc.

Stock Analysis

last close $2.81
1-mo return -35.8%
3-mo return -31.3%
avg daily vol. 2.97M
52-week high 6.5
52-week low 2.43
market cap. $448M
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. $13M
inst own. 26.7%

Subscribe now for daily local and international financial news